News | January 03, 2022
U.S. FDA grants EUA for Pfizer-BioNTech booster for 12 years and older
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
This product will be manufactured at Lupin's Goa facility in India
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
Subscribe To Our Newsletter & Stay Updated
